Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV · Electoral Command Center

On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults…